shutterstock_1201562074_designer491

designer491 / Shutterstock.com

29 April 2019Americas

LSPN 19: Humira litigation may prompt more antitrust scrutiny

The six antitrust class-action lawsuits that have been brought against AbbVie could result in more scrutiny of settlement agreements between the innovator and the biosimilar manufacturer, with potential antitrust complications.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent